Loading…
Lobbying Spend
—
Filings
39
Firms Hired
1
Active Period
2010–2019
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Consolidated Appropriations Act, 2018
2019 · first_quarter · Firm: WILLIAMS AND JENSEN, PLLC
Policies implemented pursuant to H.R. 1625, the Consolidated Appropriations Act.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 1625
An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018.
2018 · fourth_quarter · Firm: WILLIAMS AND JENSEN, PLLC
Tax issues affecting the pharmaceutical industry; Foreign direct investment, orphan drug tax credit, tax issues; Implementation of H.R. 1, Tax Cuts and Jobs Act (P.L. 115-97).
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1
Consolidated Appropriations Act, 2018
2018 · fourth_quarter · Firm: WILLIAMS AND JENSEN, PLLC
Policies impacting Medicare Part D. Policies relating to H.R. 1625, Consolidated Appropriations Act.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1625
American Health Care Act of 2017
2018 · fourth_quarter · Firm: WILLIAMS AND JENSEN, PLLC
Policies related to H.R. 1628, American Healthcare Act of 2017; General education about policies that impact pharmaceutical development approval and reimbursement; General education about FDA approval policies and NIH research activities. Education concerning pediatric rare diseases; legislation affecting orphan drugs and rare diseases; Compassionate use policies and proposals; Medicare Payment Reform.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1628
An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018.
2018 · third_quarter · Firm: WILLIAMS AND JENSEN, PLLC
Tax issues affecting the pharmaceutical industry; Foreign direct investment, orphan drug tax credit, tax issues; Implementation of H.R. 1, Tax Cuts and Jobs Act (P.L. 115-97).
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1
Consolidated Appropriations Act, 2018
2018 · third_quarter · Firm: WILLIAMS AND JENSEN, PLLC
Policies impacting Medicare Part D. Policies relating to H.R. 1625, Consolidated Appropriations Act.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1625
American Health Care Act of 2017
2018 · third_quarter · Firm: WILLIAMS AND JENSEN, PLLC
Policies related to H.R. 1628, American Healthcare Act of 2017; General education about policies that impact pharmaceutical development approval and reimbursement; General education about FDA approval policies and NIH research activities. Education concerning pediatric rare diseases; legislation affecting orphan drugs and rare diseases; Compassionate use policies and proposals; Medicare Payment Reform.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1628
An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018.
2018 · second_quarter · Firm: WILLIAMS AND JENSEN, PLLC
Tax issues affecting the pharmaceutical industry; Foreign direct investment, orphan drug tax credit, tax issues; Implementation of H.R. 1, Tax Cuts and Jobs Act.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 1
Consolidated Appropriations Act, 2018
2018 · second_quarter · Firm: WILLIAMS AND JENSEN, PLLC
Policies impacting Medicare Part D. Policies relating to H.R. 1625, Consolidated Appropriations Act.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 1625
American Health Care Act of 2017
2018 · second_quarter · Firm: WILLIAMS AND JENSEN, PLLC
Policies related to H.R. 1628, American Healthcare Act of 2017; General education about policies that impact pharmaceutical development approval and reimbursement; General education about FDA approval policies and NIH research activities. Education concerning pediatric rare diseases; legislation affecting orphan drugs and rare diseases; Compassionate use policies and proposals; Medicare Payment Reform.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 1628
An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018.
2018 · first_quarter · Firm: WILLIAMS AND JENSEN, PLLC
Tax issues affecting the pharmaceutical industry; Foreign direct investment, orphan drug tax credit, tax issues; Implementation of H.R. 1, Tax Cuts and Jobs Act.
Client expense: — · Firm income: —
Matched citations: H.R. 1
Consolidated Appropriations Act, 2018
2018 · first_quarter · Firm: WILLIAMS AND JENSEN, PLLC
Policies impacting Medicare Part D, H.R. 1625, Consolidated Appropriations Act.
Client expense: — · Firm income: —
Matched citations: H.R. 1625
American Health Care Act of 2017
2018 · first_quarter · Firm: WILLIAMS AND JENSEN, PLLC
H.R. 1628, American Healthcare Act of 2017; General education about policies that impact pharmaceutical development approval and reimbursement; FDA Reauthorization Act of 2017; general education about FDA approval policies and NIH research activities. Education concerning pediatric rare diseases; legislation affecting orphan drugs and rare diseases; FDA priority review voucher program authorization; Compassionate use policies and proposals; Medicare Payment Reform.
Client expense: — · Firm income: —
Matched citations: H.R. 1628
An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018.
2018 · first_quarter · Firm: WILLIAMS AND JENSEN, PLLC
Tax issues affecting the pharmaceutical industry; Foreign direct investment, orphan drug tax credit, tax issues; Implementation of H.R. 1, Tax Cuts and Jobs Act.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 1
Consolidated Appropriations Act, 2018
2018 · first_quarter · Firm: WILLIAMS AND JENSEN, PLLC
Policies impacting Medicare Part D, H.R. 1625, Consolidated Appropriations Act.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 1625
American Health Care Act of 2017
2018 · first_quarter · Firm: WILLIAMS AND JENSEN, PLLC
H.R. 1628, American Healthcare Act of 2017; General education about policies that impact pharmaceutical development approval and reimbursement; FDA Reauthorization Act of 2017; general education about FDA approval policies and NIH research activities. Education concerning pediatric rare diseases; legislation affecting orphan drugs and rare diseases; FDA priority review voucher program authorization; Compassionate use policies and proposals; Medicare Payment Reform.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 1628
An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018.
2017 · fourth_quarter · Firm: WILLIAMS AND JENSEN, PLLC
Tax issues affecting the pharmaceutical industry; Foreign direct investment, orphan drug tax credit, tax reform, H.R. 1, Tax Cuts and Jobs Act.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1
American Health Care Act of 2017
2017 · fourth_quarter · Firm: WILLIAMS AND JENSEN, PLLC
H.R. 1628, American Healthcare Act of 2017; the better Care Reconciliation Act; General education about policies that impact pharmaceutical development approval and reimbursement; FDA Reauthorization Act of 2017; general education about FDA approval policies and NIH research activities. Education concerning pediatric rare diseases; legislation affecting orphan drugs and rare diseases; FDA priority review voucher program authorization; Compassionate use policies and proposals; Medicare Payment Reform.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1628
An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018.
2017 · fourth_quarter · Firm: WILLIAMS AND JENSEN, PLLC
Tax issues affecting the pharmaceutical industry; Foreign direct investment, orphan drug tax credit, tax reform, H.R. 1, Tax Cuts and Jobs Act.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1
American Health Care Act of 2017
2017 · fourth_quarter · Firm: WILLIAMS AND JENSEN, PLLC
H.R. 1628, American Healthcare Act of 2017; the better Care Reconciliation Act; General education about policies that impact pharmaceutical development approval and reimbursement; FDA Reauthorization Act of 2017; general education about FDA approval policies and NIH research activities. Education concerning pediatric rare diseases; legislation affecting orphan drugs and rare diseases; FDA priority review voucher program authorization; Compassionate use policies and proposals; Medicare Payment Reform.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1628
American Health Care Act of 2017
2017 · third_quarter · Firm: WILLIAMS AND JENSEN, PLLC
H.R. 1628, American Healthcare Act of 2017; the better Care Reconciliation Act; S. 204, Trickett Wendler Right to Try Act; H.R. 878 Right to Try; general education about policies that impact pharmaceutical development approval and reimbursement; H.R. 2430, S. 934, FDA Reauthorization Act of 2017; general education about FDA approval policies and NIH research activities. Education concerning pediatric rare diseases; legislation affecting orphan drugs and rare diseases; FDA priority review voucher program authorization; Compassionate use policies and proposals; Medicare Payment Reform.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 1628
FDA Reauthorization Act of 2017
2017 · third_quarter · Firm: WILLIAMS AND JENSEN, PLLC
H.R. 1628, American Healthcare Act of 2017; the better Care Reconciliation Act; S. 204, Trickett Wendler Right to Try Act; H.R. 878 Right to Try; general education about policies that impact pharmaceutical development approval and reimbursement; H.R. 2430, S. 934, FDA Reauthorization Act of 2017; general education about FDA approval policies and NIH research activities. Education concerning pediatric rare diseases; legislation affecting orphan drugs and rare diseases; FDA priority review voucher program authorization; Compassionate use policies and proposals; Medicare Payment Reform.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 2430
Right to Try Act of 2017
2017 · third_quarter · Firm: WILLIAMS AND JENSEN, PLLC
H.R. 1628, American Healthcare Act of 2017; the better Care Reconciliation Act; S. 204, Trickett Wendler Right to Try Act; H.R. 878 Right to Try; general education about policies that impact pharmaceutical development approval and reimbursement; H.R. 2430, S. 934, FDA Reauthorization Act of 2017; general education about FDA approval policies and NIH research activities. Education concerning pediatric rare diseases; legislation affecting orphan drugs and rare diseases; FDA priority review voucher program authorization; Compassionate use policies and proposals; Medicare Payment Reform.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 878
Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017
2017 · third_quarter · Firm: WILLIAMS AND JENSEN, PLLC
H.R. 1628, American Healthcare Act of 2017; the better Care Reconciliation Act; S. 204, Trickett Wendler Right to Try Act; H.R. 878 Right to Try; general education about policies that impact pharmaceutical development approval and reimbursement; H.R. 2430, S. 934, FDA Reauthorization Act of 2017; general education about FDA approval policies and NIH research activities. Education concerning pediatric rare diseases; legislation affecting orphan drugs and rare diseases; FDA priority review voucher program authorization; Compassionate use policies and proposals; Medicare Payment Reform.
Client expense: — · Firm income: $60,000
Matched citations: S. 204
FDA Reauthorization Act of 2017
2017 · third_quarter · Firm: WILLIAMS AND JENSEN, PLLC
H.R. 1628, American Healthcare Act of 2017; the better Care Reconciliation Act; S. 204, Trickett Wendler Right to Try Act; H.R. 878 Right to Try; general education about policies that impact pharmaceutical development approval and reimbursement; H.R. 2430, S. 934, FDA Reauthorization Act of 2017; general education about FDA approval policies and NIH research activities. Education concerning pediatric rare diseases; legislation affecting orphan drugs and rare diseases; FDA priority review voucher program authorization; Compassionate use policies and proposals; Medicare Payment Reform.
Client expense: — · Firm income: $60,000
Matched citations: S. 934
Source: Senate LDA